Seminar: Combining CRISPR and Transposon-based Technologies for Improved CAR-T Therapies

Join us at CIMA (Center for Applied Medical Research) for a seminar on Combining CRISPR and transposon-based technologies for improved CAR-T therapies

Wednesday, June 12, 2024
2:30 - 3:30 pm (Spain)

In-Person Event
(Center for Applied Medical Research)
Av. de Pío XII, 55
31008 Pamplona, Navarra

About the seminar

MaxCyte is hosting a cell engineering seminar on Wednesday, June 12th from 2:30pm - 3:30pm CEST at CIMA, Pamplona.

Register to hear how guest speaker Juan R. Rodriguez uses MaxCyte's scalable transfection platforms to engineer primary cells while maintaining high efficiency and viability regardless of application. Anna Otal and Alicia Roig from the MaxCyte will be onsite to further discuss your applications.

Snacks and coffee is on us!


Juanro Foto

Juan R. Rodriguez-Madoz, PhD

Researcher at CIMA Universidad de Navarra

Juan R. Rodriguez-Madoz obtained his PhD degree in Biology in 2005 at the University of Navarra. After a postdoctoral stay at the Mount Sinai School of Medicine in New York (USA), he joined the Hemato-Oncology Program at the Cima Universidad de Navarra, where he is principal investigator of the Immune Therapy Laboratory. His research lines is focused on the development of improved CAR T therapies for hematological malignances, by combining state-of-the-art genome editing and non-viral technologies. His laboratory is also focused on the understanding of molecular mechanisms governing CAR-T cell function, combining multiomic approaches at single cell level with artificial intelligence.


Alicia Roig-Merino

Alicia Roig-Merino, PhD

Senior Field Application Scientist
MaxCyte, Inc.

Alicia Roig-Merino completed her Biology studies at the Autonomous University of Barcelona in Spain in 2013. After, she spent 2 years as research assistant broadening her skillset and knowledge in different areas such as cancer biology (Moores Cancer Center, San Diego), plant physiology (Autonomous University of Barcelona) or developmental biology and animal models (EMBL, Germany). After sampling different biology fields, she embarked on a PhD journey at the German Cancer Research Center (DKFZ), establishing a new DNA Episomal platform for the genetic engineering of stem cells. After completing her PhD in 2018, she stayed in the lab for 2 years as postdoc and applied her findings to develop an episomal therapy to correct Fanconi Anemia. During her years in the lab, her focus has been cell and genetic engineering using a variety of viral and non-viral methods, mainly electroporating cells and optimizing the best electroporation conditions for mESC and hiPSC; so it comes as no surprise she joined MaxCyte in 2020 as Field Application Specialist and ExPERT in technical applications.


Anna Navarro

Anna Otal Navarro

Business Development Manager
MaxCyte, Inc.

Anna Otal is the MaxCyte Sales Manager for Spain, Portugal and Italy. She earned an MS. in immunology from the University of Barcelona and worked in the field of microbiology and immunology at University of Otago and TUM. Also, she brings 8 years of experience supporting scientists with comprehensive workflow solutions.

Register today

Fill the form below to register.